Table 1.

Baseline characteristics and laboratory findings with posttreatment changes.

Group	Placebo	Fenofibrate	Rosiglitazone	Combined	ANOVA
	N = 10	N = 9	N = 8	N = 7	Rank
	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD	P-value
Age	57.4 ± 11.1	61.2 ± 11.6	57.3 ± 8.4	54.7 ± 9.5
M : F	6 : 4	3 : 6	5 : 3	3 : 4
Pre-TG	206 ± 65	278 ± 126	234 ± 58	239 ± 73	P = 0.212
Post-TG	202 ± 53	192 ± 64	240 ± 115	172 ± 27
(%Δ)	(7.6% ± 51.0%)	(−2.2% ± 26.0%)	(7.4% ± 48.9%)	(20.0% ± 36.5%)
Pre-HDL-C	48 ± 9	41 ± 8	52 ± 19	52 ± 14	P = 0.342
Post-HDL-C	48 ± 9	47 ± 7	50 ± 17	53 ± 9
(%Δ)	(1.7% ± 10.5%)	(14.5% ± 21.6%)	(1.9% ± 24.6%)	(5.8% ± 16.4%)
Pre-LDL-C	124 ± 46	111 ± 40	145 ± 24.6%	106 ± 41	P = 0.692
Post-LDL-C	128 ± 39	118 ± 32	140 ± 41	102 ± 31
(%Δ)	(13.7% ± 47.8%)	(2.6% ± 29.3%)	(−.5% ± 27.4%)	(37.3% ± 141.6%)
± pre-Tot C	204.4 ± 57.9	213.6 ± 39.0	238.4 ± 39.5	215.7 ± 36.6	P = 0.372
Post-Tot C	227.4 ± 37.2	199.0 ± 51.2	230.9 ± 52.2	201.1 ± 36.5
(%Δ)	(25.8% ± 70.2%)	(−7.7% ± 26.1%)	(−2.3% ± 21.3%)	(−5.0% ± 21.6%)